Fri, June 14, 2024
[ 12:00 AM ] - WOPRAI
Thu, May 2, 2024
[ 12:00 AM ] - WOPRAI
Thu, April 18, 2024
[ 12:00 AM ] - WOPRAI
Thu, August 3, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, May 4, 2023
[ 12:00 AM ] - WOPRAI
Tue, May 2, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, June 29, 2022
[ 12:00 AM ] - WOPRAI
Fri, February 25, 2022
[ 12:00 AM ] - WOPRAI
Wed, December 1, 2021
[ 12:00 AM ] - WOPRAI
Thu, October 14, 2021
Wed, January 22, 2020
[ 12:00 AM ] - WOPRAI
Thu, August 1, 2019
[ 12:00 AM ] - WOPRAI
Fri, October 28, 2016
Fri, April 29, 2016
Thu, March 31, 2016
[ 12:00 AM ] - WOPRAI
Mon, December 23, 2013
[ 12:00 AM ] - WOPRAI
Mon, April 30, 2012
Matthew Kaplan Maintained (URGN) at Strong Buy with Increased Target to $54 on, Jun 14th, 2024
Matthew Kaplan of Ladenburg Thalmann, Maintained "UroGen Pharma Ltd." (URGN) at Strong Buy with Increased Target from $48 to $54 on, Jun 14th, 2024.
Matthew, nor any peers, have made any analyst calls on URGN in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources